Clinical Trials Logo

Fetal Growth clinical trials

View clinical trials related to Fetal Growth.

Filter by:
  • None
  • Page 1

NCT ID: NCT06268392 Not yet recruiting - Clinical trials for Fetal Growth Retardation

A Comparative Study of AI Methods for Fetal Diagnostic Accuracy in Ultrasound

Start date: February 15, 2024
Phase:
Study type: Observational

This study serves as a supplemental investigation to the randomized controlled SCAN-AID study (NCT0632187). This study will evaluate and compare the fetal growth estimation outcomes of AI-supported groups, expert sonographers, and control groups using a secondary AI predictive model.

NCT ID: NCT04801121 Enrolling by invitation - Clinical trials for Magnetic Resonance Imaging

Fetal Growth and Placental Function in Pregnancies Complicated by Diabetes

FaPDi
Start date: November 1, 2020
Phase:
Study type: Observational [Patient Registry]

Diabetic pregnancies are often complicated by placental dysfunction with reduced transfer of oxygen from the mother to the fetus, which may compromise fetal growth and organ development. In diabetic pregnancies, hyperinsulinemia and hyperglycemia very often leads to fetal macrosomia. The combination of reduced placental oxygen transfer and increasing fetal demand due to fetal overgrowth may possess a particular risk of adverse pregnancy outcome. Current methods in the antenatal identification of placental dysfunction relies on estimates of fetal size and fetal wellbeing using ultrasound including Doppler flows measurements. These measurements are only indirect estimates of placental function, as no clinical method exists to assess placental function directly. In diabetic pregnancies, the estimates are further limited due to fetal overgrowth and unreliable Doppler. In addition, in diabetic pregnancies, intrauterine fetal weight estimates by ultrasound are inaccurate because of asymmetric fetal growth. Therefore, new accurate methods to assess placental function, fetal oxygenation and fetal growth in this particular group of high-risk pregnancies is highly needed. Early and precise identification of pathology in diabetes pregnancy may lead to an improved outcome in the offspring, as precise identification of pathology facilitates important obstetric decisions in regards to maternal antidiabetic treatment and timing of delivery. Resent research indicates that MRI is useful for this purpose. It is well described, that preeclampsia is associated with an increased maternal risk of cardiovascular disease later in life. Recent studies suggest, that pregestational subclinical cardiovascular dysfunction, in particular left ventricular dysfunction, may increase the risk of preeclampsia and fetal growth restriction during pregnancy. Cardiac MRI is a sensitive method to detect subclinical maternal cardiac dysfunction, which may be used in identification of high-risk pregnancies. In addition, the longitudinal design of this study allows for the investigation of cardiovascular changes during pregnancies in normal pregnancies and pregnancies complicated by diabetes. The overall aim of this study is to improve the antenatal fetal and maternal monitoring in diabetes pregnancies. Early and precise identification of pregnancy pathology provides a better basis for important obstetric decisions regarding antidiabetic treatment, monitoring intervals and timing of delivery, which leads to a better outcome for the mother and offspring. Hypothesis Project A: Placental function and fetal oxygenation in diabetic pregnancies estimated by T2* weighted placental and fetal MRI Aim: To investigate placental function and fetal oxygenation by longitudinal T2* weighted placental MRI and the association with pregnancy complications. Hypothesis: - Diabetic pregnancies are characterized by placental hypoxia (low T2* value) - Diabetic pregnancies are characterized by fetal hypoxia (low T2* value) - Fetal and placental hypoxia is a risk factor of placental related complications in pregnancy such as low birth weight, preterm delivery, acute cesarean sections and preeclampsia. Project B: Fetal growth and the growth of selected fetal organs in diabetic pregnancies estimated by longitudinal MRI volumetry Aim: To investigate growth velocity of the fetus and selected fetal organs and the correlation with pregnancy complications. Hypothesis: - Diabetic pregnancies are characterized by accelerated fetal growth in the third trimester - Diabetic pregnancies are characterized by asymmetric growth (reduced brain/liver-volume ratio) - Abnormal fetal growth is associated with dysregulated maternal diabetes. - Abnormal fetal growth is a risk factor of pregnancy complications such as; macrosomia, preterm delivery and acute cesarean sections. Project C: Maternal cardiac function in diabetic pregnancies estimated by MRI Aim: To investigate maternal cardiac function and the correlation with pregnancy complications such as preeclampsia and fetal growth restriction. Hypothesis: - Maternal cardiac function is altered in diabetes pregnancies when compared to normal pregnancies. - Impaired cardiac function (left ventricular dysfunction) is a risk factor of preeclampsia and fetal growth restriction.

NCT ID: NCT02692924 Completed - Fetal Growth Clinical Trials

Fetal Body Composition and Volumes Study

Start date: February 25, 2016
Phase:
Study type: Observational

Background: Gravid diseases are complications in pregnancy. They include gestational diabetes and preeclampsia. These can cause problems with how a fetus grows. Being pregnant with twins can make complications more likely. Research suggests that changes in fetal soft tissue may be the earliest signs of growth problems. These tissue changes are in lean mass, fat mass, and organ size. 3D images might detect these changes earlier than 2D images. This could help manage gravid diseases. The NICHD Fetal Growth Studies - Singletons measured fetal growth for four racial groups, Caucasian, African American, Asian, and Hispanic. Fetuses of obese women and women with twins were also measured. 2D and 3D images were taken at various stages of pregnancy. Measurements were taken after birth. Researchers want to expand this study by measuring organ volumes and body composition by racial group and in twins. Objectives: To set standards for body composition and organ volumes by race. To understand the relationship between gravid diseases and changes in fetal body composition and organ volume over the course of pregnancy. To find out whether these are different for twins than for single pregnancies. Eligibility: Women who participated in the NICHD Fetal Growth Studies - Singletons and Twins. Design: The data will come from the NICHD Fetal Growth Studies - Singletons and Twins. Researchers will review scans taken in the previous study. They will take measurements from the scans.

NCT ID: NCT00957476 Completed - Obesity Clinical Trials

Omega-3 Supplementation Decreases Inflammation and Fetal Obesity in Pregnancy

Start date: September 2009
Phase: N/A
Study type: Interventional

Randomized, double-blind placebo controlled trial of fish oil to decrease inflammation in pregnancy.

NCT ID: NCT00912132 Completed - Pregnancy Clinical Trials

The National Standard for Normal Fetal Growth

Start date: May 19, 2009
Phase:
Study type: Observational

Normal fetal growth is a critical component of a healthy pregnancy and the long-term health of the offspring. Pivotal to understanding the dynamics of human fetal growth and to defining normal and abnormal fetal growth is the development of standards for fetal growth. The study's purpose was to establish standards for normal fetal growth and size for gestational age for 4 racial/ethnic groups of pregnant women with the eventual creation of individualized standards for fetal growth and improvements in fetal weight estimation. These data for a contemporary cohort of pregnant women should provide data for clinical management.